Publication | Closed Access
TNF-alpha and HLA-DR genotyping as potential prognostic markers in pulmonary sarcoidosis.
84
Citations
0
References
1999
Year
Inflammatory Lung DiseaseSarcoidosis PatientsAdvanced Lung DiseaseHla-dr GenotypingDisease EtiologyImmunologyGenetic EpidemiologyPathologyHuman PolymorphismImmune-related Gene PolymorphismDisease SusceptibilityPublic HealthMolecular DiagnosticsPotential Prognostic MarkersHla-drb1 AllelesRheumatologyAutoimmune DiseasePulmonary FibrosisAutoimmunityPulmonary MedicinePulmonary SarcoidosisPulmonary DiseasePulmonary Vascular DiseaseSarcoidosis GroupHla TypingMedicineMatrikines
We have analyzed the HLA-DRB1 alleles and -308 TNF-alpha gene polymorphism in 78 sarcoidosis patients and 50 controls. The sarcoidosis group as a whole did not show any significant correlation with the TNF-A or the HLA-DR alleles compared to the control group. However, the patient subgroups of Löfgren and non-Löfgren sarcoidosis exhibited significant allele associations. In the Löfgren patient group, the TNF-A2 and the HLA-DR3 alleles were represented significantly higher, with a highly significant relative risk resulting from the presence of the TNF-A2 or the HLA-DR3 allele or both. In the non-Löfgren patient group, the phenotype expressing HLA-DR2 and lacking TNF-A2 was significantly higher than in the Löfgren patient group. Due to these significant genetic differences in the subgroups of Löfgren and non-Löfgren sarcoidosis patients, we conclude that the genotyping of these two loci (-308 TNF-alpha promoter polymorphism and HLA-DR) may be of prognostic value for the course of disease in sarcoidosis.